Lygenesis
Pittsburgh, US · Founded 2017 · Delaware corporation · 8 employees on LinkedIn · 2 known investors
Find your way into Lygenesis
857 people in our graph share verified history with the Lygenesis team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Eric Lagasse · together at Stanford University (overlapped)
×9knows the team · via Stanford University
knows the team · via MIT Sloan School of Management
knows the team · via Eikonoklastes Therapeutics, Inc.
LyGenesis is a clinical-stage cell therapy company that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its allogeneic cell therapies target diseases including end stage liver disease, end stage renal disease, Type 1 diabetes, and aging of the thymus.
Founders & leadership
Lygenesis was founded in 2017 by Eric Lagasse, Michael Hufford, Paulo Fontes, and Eric Legasse.
EL
Eric LagasseinCo-founder · Chief Scientific OfficerEric Lagasse is an executive officer and director at Lygenesis, a clinical-stage cell therapy company developing ectopic organ therapies. He completed postdoctoral research in stem cell biology at Stanford University and has held academic positions involving research, teaching, and leadership.
MH
PF
Paulo FontesinCo-founder & Chief Medical OfficerPaulo Fontes is a transplant surgeon and biotech entrepreneur who completed medical training at UNESP in Brazil and served as a Professor of Surgery at the University of Pittsburgh, where he directed a liver transplant program and held leadership roles at the McGowan Institute for Regenerative Medicine. He has founded multiple biotechnology companies developing cell-based and regenerative therapies over a 13-year entrepreneurial career following 27 years in academic medicine.
EL
Eric LegasseCo-founder
GB
Gregory BaileyNamed on SEC filing
Board
JM
James MellonBoard director
SF
Steve FelsteadBoard director
JB
Justin Briggsin𝕏Board MemberScientist, entrepreneur, and investor building companies at the nexus of biology, chemistry, and engineering
Investors · 2
Reported raises · per SEC filings
Form D private placements$25.8M disclosed across 4 rounds · 2018–2023
▶$17.8MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
▶$17.8MraisedOct 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James MellonDirector
- Steve FelsteadDirector
- Eric LagasseExecutive Officer, Director
- Justin BriggsDirector
- Michael HuffordExecutive Officer, Director, Promoter
- Offering amount
- $20M
- Amount sold
- $17.8M
- Proceeds to insiders
- $1.6M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedDec 2020 · 7 investors · BiotechnologyRule 506(b)
▶$1.9MraisedDec 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HuffordExecutive Officer, Director, Promoter
- Eric LagasseExecutive Officer
- Paulo FontesExecutive Officer
- James MellonDirector
- Offering amount
- $20.5M
- Amount sold
- $1.9M
- Proceeds to insiders
- $1.1M
- First sale
- Dec 2020
- Incorporated
- Corporation, De, 2017
- Federal exemptions
- 06b
▶$4MraisedOct 2019 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedOct 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric LegasseExecutive Officer, Promoter
- Paulo FontesExecutive Officer, Promoter
- Michael HuffordExecutive Officer, Director, Promoter
- Gregory BaileyDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Proceeds to insiders
- $895K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.2MraisedMay 2018 · 2 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paulo FontesExecutive Officer, Promoter
- Eric LegasseExecutive Officer, Promoter
- Gregory BaileyDirector
- Michael HuffordExecutive Officer, Director, Promoter
- Offering amount
- $3.2M
- Amount sold
- $2.2M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapOrgenesis11 shared keywordsOrgenesis provides decentralized manufacturing infrastructure for cell and gene therapies, enabling on-site processing of CGTs in regional centers through its POCare™ platform and OMPUL™ mobile processing units. The company aims to reduce costs, shorten development timelines, and improve patient access to personalized cell and gene therapies.
eGenesis9 shared keywordseGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
Organogenesis6 shared keywordsOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Genesis Molecular AI5 shared keywordsGenesis develops GEMS, an AI platform for drug discovery that identifies and optimizes drug candidates. The company partners with pharmaceutical firms like Incyte and Gilead to accelerate the identification and optimization of new drugs.
Thiogenesis Therapeutics4 shared keywordsThiogenesis Therapeutics is a clinical-stage biopharmaceutical company developing sulfur-based therapeutic compounds to treat oxidative stress and inflammation in mitochondrial diseases. The company is advancing TTI-0102, a novel cysteamine prodrug candidate, for rare inherited and acquired mitochondrial disorders including nephropathic cystinosis and Leigh syndrome.
Amogy3 shared keywordsAmogy develops patented ammonia cracking technology that converts ammonia into electric power for hydrogen fuel cells and engines, targeting decarbonization of heavy industries including transportation and maritime. The company offers modular ammonia-to-power systems and high-efficiency catalysts as alternatives to diesel and hydrogen fuel solutions.
Companies competing with Lygenesis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Lygenesis do?
- LyGenesis is a clinical-stage cell therapy company that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its allogeneic cell therapies target diseases including end stage liver disease, end stage renal disease, Type 1 diabetes, and aging of the thymus.
- Who founded Lygenesis?
- Lygenesis was founded by Eric Lagasse, Michael Hufford, Paulo Fontes, Eric Legasse in 2017.
- Who are Lygenesis's investors?
- Lygenesis's investors include Prime Movers Lab, Peak State Ventures.
- How much funding has Lygenesis raised?
- Lygenesis has disclosed $25.8M raised across 4 rounds.
- Where is Lygenesis headquartered?
- Lygenesis is headquartered in Pittsburgh, US.